Nanotechnology in Drug-Eluting Cardiovascular Stents
Nanotechnology is transforming cardiovascular care by enabling more efficient drug delivery in drug-eluting stents (DES). These stents, traditionally designed to release antiproliferative agents to prevent restenosis, are now leveraging nanoscale coatings and structures to improve precision, bioavailability, and biocompatibility.
Nanostructured surfaces on stents can be engineered to optimize endothelial cell growth while inhibiting smooth muscle cell proliferation, reducing the likelihood of late stent thrombosis. Nano-coatings also allow for controlled, sustained drug release, ensuring therapeutic agents are delivered exactly where needed without systemic side effects.
Recent advancements include polymer-free nano-engineered stents, where the drug is embedded directly into the nanostructured metal surface. This eliminates the risk of polymer-related inflammation and accelerates healing. Researchers are also exploring nanoparticle carriers that can deliver combination therapies, targeting multiple pathways in vascular healing simultaneously.
Nanotechnology enables thinner stent struts without compromising strength, improving blood flow and reducing vascular injury during placement. These innovations not only improve patient outcomes but also allow for shorter durations of dual antiplatelet therapy.
As research advances, clinical trials are essential to validate long-term safety and efficacy. The integration of nanotechnology into DES design marks a significant step forward in personalized cardiovascular interventions.